title: Chinese Herbal Medicine Xingnaojing Injection () for Hypoxic Ischemic Encephalopathy in Newborns: A Systematic Review and Meta-Analysis.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of Chinese herbal medicine Xingnaojing Injection () for newborns with hypoxic ischemic encephalopathy (HIE).
  
  
  METHODS
  Literatures were identified by searching the PubMed, EMBASE, Cochrane Library, Cochrane Central, and four Chinese literature databases from the establishment of database to October in 2013. Relevant reference lists were also screened. Two reviewers independently evaluated the methodological quality of included studies. We also conducted the meta-analysis.
  
  
  RESULTS
  Thirteen trials involving 1,169 patients were included. There was no trial reported death or disability at the end of follow-up period. Meta-analysis of 4 trials (n=371) showed that there was no significant difference in the reduction of mortality [risk ratios (RR)=0.48, 95% confidence intervals (CI, 0.21, 1.13), P=0.09] between the Xingnaojing and control groups. Meta-analysis of 5 trials (n=359) showed that there was significant difference in reducing the major neurodevelopmental disability [RR=0.36, 95% CI (0.19, 0.66), P=0.001]. Meta-analysis of 6 trials (n=447) showed that there was significant difference in the author self-defined symptom improvement [RR=1.25, 95% CI (1.14, 1.37), P<0.01]. No fatal side-effects were reported.
  
  
  CONCLUSIONS
  Based on the limited evidence, the routine use of Xingnaojing Injection for treatment of HIE in newborns is not recommended. Further well-conducted trials are justified.
authors.affiliation: Department of Pharmacy, Evidence-Based Pharmacy Centre, West China Second Hospital, Sichuan University, Chengdu, 610041, China.|West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, 610041, China.
authors.forename: Chun-Song
authors.initials: CS
authors.lastname: Yang
authors.affiliation: Department of Pharmacy, Evidence-Based Pharmacy Centre, West China Second Hospital, Sichuan University, Chengdu, 610041, China. linyunzhu99@163.com.|West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, 610041, China. linyunzhu99@163.com.
authors.forename: Yun-Zhu
authors.initials: YZ
authors.lastname: Lin
authors.affiliation: West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, 610041, China.|Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu, 610041, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Guo
authors.affiliation: College of Chemistry and Environment Protection, Southwest University for Nationalities, Chengdu, 610041, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: He
mesh_terms: D003643:Death; D004185:Disability Evaluation; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy*; D007231:Infant, Newborn; D007267:Injections; D017741:Survivors; D016896:Treatment Outcome
chemical_list: D004365:Drugs, Chinese Herbal; C000594497:xingnaojing
keywords: Chinese herbal medicine; hypoxic ischemic encephalopathy; newborns; systematic review